Clinical evaluation of a 51Cr-labeled red blood cell survival test for in vivo blood compatibility testing.
Modified red blood cell survival studies with use of 51Cr were performed in three groups of subjects. Group 1 consisted of normal subjects who were given labeled autologous blood, group 2 were subjects in need of blood transfusions and given labeled ABO and Rh crossmatch-compatible blood, and group 3 were patients in need of blood transfusion but in whom problems arose in finding compatible blood. The results of the studies suggest that for patients with blood compatibility problems, normal red blood cell survival values at 1 hour do not exclude the possibility of severe hemolysis 24 hours later. Thus, if a 1-hour test result is normal, the procedure should be extended routinely to 24 hours. Moreover, the test can be used to evaluate the clinical importance of antibodies. We showed that anti-Yka and anti-Lan were clinically significant, but high-titer, low-avidity antibodies, anti-Kna, anti-I, and anti-HI were clinically insignificant in the cases studied. This finding emphasizes the importance of an in vivo test for the final compatibility evaluation in complicated blood replacement problems.
D000017:ABO Blood-Group System; D000328:Adult; D000906:Antibodies / Q000276:immunology; D001788:Blood Grouping and Crossmatching; D001803:Blood Transfusion; D002470:Cell Survival; D002860:Chromium Radioisotopes; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000017:ABO Blood-Group System; D000906:Antibodies; D002860:Chromium Radioisotopes